Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of bevacizumab and
lomustine can help to control glioblastoma. The safety of this combination will also be
studied.